DeutschNewstral
Article
bizjournals.com on 2020-12-16 15:14
Top former Alnylam exec Barry Greene named CEO of Sage Therapeutics
Related news
- Longtime Alnylam exec Barry Greene leaving biotechbizjournals.com
- Pittsburgh biotech names Alnylam exec as new chief commercial officerbizjournals.com
Sage Therapeutics surges on postpartum depression drug studyseattletimes.com
Does Sage Therapeutics' Failure Predict Its Future Results?Forbes- Sage Therapeutics sees modest results from tremor drug trialbizjournals.com
- Weed dispensary Sage Naturals changes name after lawsuit by Sage Therapeuticsbizjournals.com
- LFamilial Amyloid Polyneuropathy Market 2021 High Growth Forecast due to Rising Demand and Future Trends | Key Companies: Pfizer, GSK, Ionis, Alnylam, Corino Therapeutics, Proclara Bioscience, Arctu…liverpoolstudentmedia.com
- BNeurology Drug Study Does Little for Sage Therapeutics, or Its Partner Biogenbarrons.com
- Sage Therapeutics to seek approval of postpartum depression drug after trial winbizjournals.com
- BSage Therapeutics Stock Collapsed Thursday. Analysts Say It Has Fallen Enough.barrons.com
- Sage Therapeutics Takes Investors On A Wild Ride As CEO Talks Up Brain DrugsForbes
- MSage Therapeutics shares surge 45% on positive trail of postpartum depression drugmarketwatch.com
- Five things you don’t know about Jeff Jonas, CEO of Sage Therapeuticsbizjournals.com
- BSage Therapeutics Lays Off Staff to Save Cash After Failed Drug Trialbarrons.com
- New Drug Eases Postpartum Depression In Victory For Tiny Sage TherapeuticsForbes
FDA Approves Sage Therapeutics’ Zulressowsj.com- KPulmonary Edema Market Growing Demand with Innovative Ideas Adopted by Key Players – Gilead Sciences Inc., Merck & Co, Jazz Pharmaceuticals Plc, Sage Therapeuticsksusentinel.com
Sage Therapeutics, Dollar General jump; LendingClub tumblesChicago Tribune- Alnylam plans Cambridge expansion after $2B investmentbizjournals.com